Paul G. Wyatt
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul G. Wyatt.
Bioorganic & Medicinal Chemistry Letters | 2002
Paul G. Wyatt; Michael J. Allen; Josie Chilcott; Christopher J. Gardner; David G. Livermore; Jackie E. Mordaunt; Fabrizio Nerozzi; Mamta Patel; Marion J. Perren; Gordon G. Weingarten; Shalia Shabbir; Patrick M. Woollard; Ping Zhou
The paper covers continuing efforts to discover novel, potent and selective oxytocin antagonists. Further benzofuran derivatives with potent oxytocin antagonist activity and good pharmacokinetic parameters are reported. Efforts to improve the in vivo activity of the series are described.
Bioorganic & Medicinal Chemistry Letters | 2001
Paul G. Wyatt; Michael J. Allen; Josie Chilcott; Gwen Hickin; Neil Derek Miller; Patrick M. Woollard
We have investigated the structure-activity relationships of the 1- and 3-substituents and replacements of the 5-phenyl group of GW405212X 1, a potent selective oxytocin antagonist. The effect of these modifications on oxytocin binding antagonism and on pharmacokinetic parameters is reported.
Bioorganic & Medicinal Chemistry Letters | 2002
Paul G. Wyatt; Michael J. Allen; Josie Chilcott; Alison Foster; David G. Livermore; Jackie E. Mordaunt; Jan J. Scicinski; Patrick M. Woollard
Studies to discover novel, potent and selective oxytocin antagonists are reported. Combinatorial libraries designed to find novel replacements of fragments of oxytocin antagonist L-371,257, identified pyrimidine, thiazole, indole and benzofuran as potential alternatives to the benzoic acid moiety of L-371,257. Additional investigations identified indole and benzofuran derivatives with potent oxytocin antagonist activity.
Chemistry: A European Journal | 2018
Nicola Luise; Paul G. Wyatt
Synthesising polar semi-saturated bicyclic heterocycles can lead to better starting points for fragment-based drug discovery (FBDD) programs. We report the application of diverse chemistry to construct bicyclic systems from a common intermediate, where pyrazole, a privileged heteroaromatic able to bind effectively to biological targets, is fused to diverse saturated counterparts. The generated fragments can be further developed either after confirmation of their binding pose or early in the process, as their synthetic intermediates. Essential quality control (QC) for selection of small molecules to add to a fragment library is discussed.
Bioorganic & Medicinal Chemistry Letters | 2005
Paul G. Wyatt; Michael J. Allen; Alan D. Borthwick; Dave E. Davies; Anne M. Exall; Richard Jonathan Hatley; Wendy R. Irving; David G. Livermore; Neil Derek Miller; Fabrizio Nerozzi; Steve L. Sollis; Anna Katrin Szardenings
Journal of Organic Chemistry | 1996
Masumi Asakawa; Christopher L. Brown; Dario Pasini; Stoddart Jf; Paul G. Wyatt
Chemistry: A European Journal | 1998
Peter R. Ashton; Sue E. Boyd; Stephan Menzer; Dario Pasini; Françisco M. Raymo; Neil Spencer; J. Fraser Stoddart; Andrew J. P. White; David J. Williams; Paul G. Wyatt
Archive | 2002
Alan David Borthwick; Richard Jonathan Hatley; Deirdre Mary Bernadette Hickey; John Liddle; David G. Livermore; Andrew Mcmurtrie Mason; Neil Derek Miller; Fabrizio Nerozzi; Steven Leslie Sollis; Anna Katrin Szardenings; Paul G. Wyatt
Annual Reports in Medicinal Chemistry | 1995
Richard E. Boehme; Alan D. Borthwick; Paul G. Wyatt
Archive | 2002
Alan David Borthwick; Richard Jonathan Hatley; Deirdre Mary Bernadette Hickey; John Liddle; David G. Livermore; Andrew Mcmurtrie Mason; Neil Derek Miller; Fabrizio Nerozzi; Steven Leslie Sollis; Anna Katrin Szardenings; Paul G. Wyatt